Corrigendum: Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies

• Paul Noe,
• Joy H. Wang,
• Kyu Chung,
• Zhiyong Cheng,
• Jessica J. Field,
• Xiaomeng Shen,
• Stephanie C. Casey,
• Christa L. Cortesio,
• Cinthia V. Pastuskovas,
• Hyewon Phee,
• Kristin V. Tarbell,
• Jackson G. Egen,
• Amy-Jo Casbon

Affiliations

Paul Noe

Oncology Research, Amgen Research, South San Francisco, CA, United States

Joy H. Wang

Oncology Research, Amgen Research, South San Francisco, CA, United States

Kyu Chung

Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, CA, United States

Zhiyong Cheng

Oncology Research, Amgen Research, South San Francisco, CA, United States

Jessica J. Field

Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, CA, United States

Xiaomeng Shen

Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, CA, United States

Stephanie C. Casey

Oncology Research, Amgen Research, South San Francisco, CA, United States

Christa L. Cortesio

Therapeutics Discovery, Amgen Research, South San Francisco, CA, United States

Cinthia V. Pastuskovas

Pharmacokinetics and Drug Metabolism, Amgen Research, South San Francisco, CA, United States

Hyewon Phee

Oncology Research, Amgen Research, South San Francisco, CA, United States

Kristin V. Tarbell

Oncology Research, Amgen Research, South San Francisco, CA, United States

Jackson G. Egen

Oncology Research, Amgen Research, South San Francisco, CA, United States

Amy-Jo Casbon

Oncology Research, Amgen Research, South San Francisco, CA, United States